M
Mindy C. Kohlhagen
Researcher at Mayo Clinic
Publications - 31
Citations - 518
Mindy C. Kohlhagen is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Immunoglobulin light chain. The author has an hindex of 8, co-authored 24 publications receiving 338 citations.
Papers
More filters
Journal ArticleDOI
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.
John Mills,Mindy C. Kohlhagen,Surendra Dasari,Patrick M. Vanderboom,Robert A. Kyle,Jerry A. Katzmann,Maria Alice V. Willrich,David R. Barnidge,Angela Dispenzieri,David L. Murray +9 more
TL;DR: In this paper, a mass spectrometry-based method called MASS-FIX was proposed to identify and quantify monoclonal proteins (M-proteins) encountered clinically.
Journal ArticleDOI
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.
Paolo Milani,Paolo Milani,David L. Murray,David R. Barnidge,Mindy C. Kohlhagen,John Mills,Giampaolo Merlini,Surendra Dasari,Angela Dispenzieri +8 more
TL;DR: MASS‐FIX has a comparable sensitivity with PEL/IFE/FLC methods and can help inform the clinical diagnosis and may prove to be a clue to the diagnosis and pathogenesis of the disease.
Journal ArticleDOI
Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays
Jerry A. Katzmann,Maria Alice V. Willrich,Mindy C. Kohlhagen,Robert A. Kyle,David L. Murray,Melissa R. Snyder,S. Vincent Rajkumar,Angela Dispenzieri +7 more
TL;DR: The use of IgA HLC assays for monitoring β-migrating IgA monoclonal proteins can substitute for the combination of SPEP, IFE, and total IgA quantification.
Journal ArticleDOI
Screening Method for M-Proteins in Serum Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry
Mindy C. Kohlhagen,David R. Barnidge,John Mills,Joshua Stoner,Kari M. Gurtner,Andrea M. Liptac,Denise I. Lofgren,Patrick M. Vanderboom,Angela Dispenzieri,Jerry A. Katzmann,Maria Alice V. Willrich,Melissa R. Snyder,David L. Murray +12 more
TL;DR: MASS-SCREEN could replace PEL in a panel that would include FLC measurements, suggesting FLC ratios need to be considered in screening for monoclonal proteins.
Journal ArticleDOI
A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference
John Mills,Mindy C. Kohlhagen,Maria Alice V. Willrich,Taxiarchis Kourelis,Angela Dispenzieri,David L. Murray +5 more
TL;DR: To the editor: Multiple myeloma is a malignant plasma cell disorder resulting in expansion of clonal plasma cells that encode for a unique monoclonal immunoglobulin (M-protein).